

cloned, and termed ADAMTS13 (a disintegrin-like metalloproteinase with thrombospondin type 1 motifs 13) (5-8). ADAMTS13-producing cells were initially identified within the liver, and then more specifically as hepatic stellate cells (9), but now it is known that ADAMTS13 is also present in platelets (10), vascular endothelial cells (11), and kidney podocytes (12). Since the discovery of ADAMTS13, severe deficiency of ADAMTS13 activity (ADAMTS13: AC) has been thought to be a unique feature of TTP, and can be caused by genetic mutations or by acquired autoantibody (ADAMTS13: INH) to this enzyme; however, these alterations are not observed in HUS patients (13, 14). It is notable that a minor population of TTP patients with the 'pentad' of symptoms has almost normal or only slightly reduced ADAMTS13: AC (15). In this regard, Tandon et al (16) reported in 1994 that approximately 80% of the patients with acquired TTP had an autoantibody against CD36. In those days, however, this finding could not be directly linked to the pathogenesis of TTP. Recently, Davis et al (17) have shown that recombinant (r)-human ADAMTS13 specifically binds to r-human CD36 in vitro. CD36 is expressed in endothelial cells, platelets, and monocytes, and has been reported to bind thrombospondin-1 (18). ADAMTS13, after secretion into the circulation, is assumed to efficiently cleave unusually large VWF multimers (UL-VWFMs) released from vascular endothelial cells as a solid-phase enzyme by binding to the cell surface. It is currently unclear whether anti-CD36 autoantibodies block ADAMTS13 binding to vascular endothelial cells, but if so, this may interfere with the efficient cleavage of UL-VWFMs by ADAMTS13 and result in TTP.

In contrast to TTP, HUS is rarely induced by genetic mutations in complement regulatory factors (factors B, H, and I, and membrane cofactor protein or CD46). HUS can also be acquired, typically following acute enterocolitis due to shigatoxin-producing *Echerichia coli* O157: H7 infection, but also rarely due to autoantibody against factor H (19).

Since 1998, our laboratory at Nara Medical University has functioned as a nation-wide referral center for TMAs via assaying ADAMTS13: AC in a large Japan-wide patient population with thrombocytopenia suspected of being TMA. As of the end of 2008, we have established a registry of 919 patients with TMAs, and have analyzed their clinical and laboratory information. Here, we describe the results of this study, and discuss the divergence of TMAs among patient groups with masked or unmasked thrombocytopenia.

Materials and Methods

Patients

Between July 1998 and December 2008, plasma samples from 1,564 patients with thrombocytopenia suspected of TMAs were referred to our laboratory with clinical and laboratory information from 426 medical institutions across Japan. All subjects provided informed consent to participate

in this study. The study protocol was approved by the Ethics Committee of Nara Medical University Hospital.

Blood sampling

Before therapeutic approaches including plasma infusion, plasma exchange, and the use of immunosuppressants, whole blood samples (-5 mL) were taken from each patient into plastic tubes containing 1/10 volume of 3.8% sodium citrate. The plasma was separated by centrifugation at $3,000 \times g$ for 15 min at 4°C , kept in aliquots at -80°C until testing, and sent to our laboratory.

Assays of plasma ADAMTS13: AC and ADAMTS13: INH

Until March 2005, ADAMTS13: AC was determined by classic VWFm assay (3) with a detection limit of 3% of the normal control (20). Thereafter, a chromogenic ADAMTS13-act-ELISA with a detection limit of 0.5% of the normal control was developed (21), and replaced the VWFm assay. Measurement of plasma levels of ADAMTS13: AC by these assays were highly correlated ($R^2=0.72$, $p<0.01$) and provided similar results for mean \pm SD in healthy individuals ($102.4 \pm 23.0\%$ vs. $99.1 \pm 21.5\%$), as shown previously (21, 22). Thus, we re-examined the plasma of 724 of the 774 TMA patients determined by the VWFm assay by act-ELISA, and the latter data were used in this study. For 50 TMA patients we were unable to re-examine by act-ELISA, the VWFm assay data were used. We have therefore tentatively categorized plasma levels of ADAMTS13: AC of $<3\%$, $3\%<25\%$, and $25\%<50\%$ of the normal as severe, moderate, and mild deficiency, respectively.

Plasma ADAMTS13: INH titers were also evaluated either by classic VWFm assay or chromogenic ADAMTS13-act-ELISA using heat-inactivated plasma at 56°C for 30 minutes (13, 14). One Bethesda unit (U) is defined as the amount necessary to reduce ADAMTS13: AC to 50% of control levels (23). Titers greater than 0.5 Bethesda U/mL were classified as inhibitor positive.

Diagnostic criteria for TMAs

According to previous reports (2, 24, 25), TMAs were defined as having all of the following: (i) microangiopathic hemolytic anemia (hemoglobin ≤ 12 g/dL), Coombs test negative, undetectable serum haptoglobin (<10 mg/dL), more than 2 fragmented red cells (schistocytes) in a microscopic field with a magnification of 100, and concurrent increased serum lactate dehydrogenase (LDH) above institutional baseline; (ii) thrombocytopenia (platelet count $\leq 100 \times 10^9/\text{L}$); and (iii) a variable severity of organ dysfunction (renal or neurological involvement) devoid of the stigmata of DIC (26).

A differential diagnosis of HUS or TTP based on routine laboratory data is usually difficult. As a rule, plasma levels of ADAMTS13: AC were first determined on all patients suspected of TMAs, and patients with severe deficiency of ADAMTS13: AC were classified as TTP regardless of clini-




Figure 1. Flow chart of categorization of patients with suspected thrombotic microangiopathies (TMAs) based on ADAMTS13 analysis. Of 1,564 patients with suspected TMAs, 324 had severe deficiency of ADAMTS13 activity and 1,240 did not. In the former category, 40 patients were categorized as USS and 284 as acquired TTP. In the latter category, 24 patients were categorized as congenital TMAs of the unknown etiology, 570 as acquired TMAs, and one patient as USS with moderately reduced plasma ADAMTS13:AC (3.4%), to whom frequent plasma infusions had been made to prevent further aggravation of cerebral infarction. The remaining 645 patients did not have TMAs and were therefore excluded from this study.

cal signs. Second, the patients were grouped as HUS or TTP based on the ‘triad’ or ‘pentad’ of clinical signs. This protocol appeared to be important, because our registry includes patients with hereditary deficiency of ADAMTS13: AC or congenital TTP (Upshaw-Schulman syndrome, USS), which generally have less severe clinical signs (often isolated thrombocytopenia) than acquired TTP.

Results and Discussion

A flow chart of patient categorization based on ADAMTS 13 analysis is shown in Fig. 1. Of the 1,564 patients referred to our laboratory, 324 (minor population) had severe deficiency of ADAMTS13: AC and 1,240 (major population) did not. In the population with severe ADAMTS13: AC de-

Table 1. Plasma Levels of ADAMTS13: AC and ADAMTS13: INH in 919 Patients with Thrombotic Microangiopathies (TMAs) Registered at Nara Medical University during July 1988- December 2008

	Congenital TMAs		Acquired TMAs											Total (n=919)
	Upshaw-Schulman syndrome (USS) (n=41)	Unknown etiology (n=24)	Idiopathic				Secondary							
			Thrombotic thrombocytopenic purpura (TTP) (n=284)	Hemolytic-uremic syndrome (HUS) (n=106)	Drug-induced			Connective tissue diseases and their allied diseases (CTDs/ADs) (n=221)	Malignancies (n=61)	Hematopoietic stem cell transplantation (HSCT) (n=54)	Pregnancy (n=15)	E. coli O157: H7 infection (n=32)	Others (Liver cirrhosis, etc) (n=46)	
					Ticlopidine (n=22)/ Clopidogrel (n=1)	Mitomycin C (n=10)	Pegylated-interferon (n=1) / Sildenafil (n=1)							
ADAMTS13:AC (%)	(n=41)	(n=24)	(n=284)	(n=106)	(n=22/n=1)	(n=10)	(n=1/n=1)	(n=221)	(n=61)	(n=54)	(n=15)	(n=32)	(n=46)	(n=919)
<3	40	0	195	0	16	0	2	46	5	0	4	0	13	324
3 ~ <25	1	4	72	20	2	2	0	66	23	18	4	5	16	233
25 ~ <50	0	9	14	48	1	5	0	66	22	24	4	17	6	216
≥50	0	11	3	38	1	3	0	43	11	12	3	10	11	146
ADAMTS13:INH (U/ml)	(n=41)	(n=23)	(n=282)	(n=43)	(n=22/n=1)	(n=7)	(n=1/n=1)	(n=167)	(n=26)	(n=15)	(n=8)	(n=17)	(n=23)	(n=697)
≥2	0	0	120	0	15	0	0	26	5	0	3	0	9	180
0.5 ~ <2	0	0	129	2	6	0	2	80	8	4	2	1	8	242
<0.5	41	23	33	41	2	7	0	79	13	11	3	16	6	275

() Sample number determined

iciency, 40 patients were categorized as USS and 284 as acquired TTP, and no patients with DIC or septic DIC were included. In the population without severe ADAMTS13: AC deficiency, 24 patients were categorized as congenital TMAs of unknown etiology, 570 as acquired TMAs, and only one patient (GG in Table 2) as USS with moderately reduced plasma ADAMTS13: AC (3.4%), to whom frequent plasma infusions had been made to prevent further aggravation of cerebral infarction. Thus, a diagnosis of USS in this patient GG was made after identifying the disease-causing mutations (C1024R/C1024R) in exon 24 by *ADAMTS13* gene analysis. These data will be published elsewhere in detail. The remaining 645 patients did not have TMAs, and were therefore excluded from this study; this group included 64 patients with DIC or septic DIC.

Congenital TMAs

Patients with repeated TMA episodes usually starting in early childhood with or without familial occurrence are usually considered as congenital TMAs; these patients are largely separated into the following two categories, on the basis of plasma levels of ADAMTS13: AC and ADAMTS 13: INH.

1. Upshaw-Schulman syndrome (USS)

USS is alternatively termed congenital TTP and is characterized by severe deficiency of ADAMTS13: AC due to genetic mutations (27). Forty-one patients (25 females and 16 males) belonging to 36 different families, were placed in this category (Table 2). All of these patients were negative for ADAMTS13: INH. USS is inherited in an autosomal recessive fashion, and therefore, the parents of patients are asymptomatic carriers with significantly reduced plasma levels of ADAMTS13: AC. The female-to-male ratio in the USS patient population is theoretically one-to-one, but our results

indicate an apparent female predominance (25 to 16). Of the 41 patients, 17 (41%) had a history of exchange blood transfusions during the newborn period, and 32 (78%) had a history of thrombocytopenia during childhood. For the remaining 9 (22%), it was unclear whether their platelet counts had been checked during that period.

ADAMTS13 gene analysis was performed for 38 USS patients, and the disease-causing mutations were identified in 37 of the 38. Of the 37 genotyped patients, 8 were homozygotes and 29 were compound heterozygotes [one *de novo* mutation (28)] for *ADAMTS13* gene mutations. Of the 8 homozygous patients, the parents of 6 had consanguineous marriages.

2. Congenital TMAs of unknown etiology

Patients in this category were characterized by repeated TMA episodes with predominant renal involvement from early childhood, and often with familial occurrence. Twenty-four patients belonging to 12 families were identified, but the etiology of TMAs in these patients remained completely unclear.

In this regard, it is well known that gene mutations in complement regulatory cofactors (factor H, factor I, factor B, and CD46 or membrane cofactor protein) cause excessive complement activation by impairing C3b inactivation, resulting in severe hemolysis, which triggers TMA episodes. Therefore, these patients are commonly termed 'congenital atypical HUS' (19). It is possible that among the patients of this category in this study, some disease might be related to gene mutations of complement regulatory cofactors, but at the time such analysis had not been done in Japan. As a first step toward such analysis, we determined the plasma levels of factor H antigen by immunoassay in our patients, and did not observe reduced levels in any patients (data not shown).

Table 2. Registration of 41 Japanese Patient with Upshaw-Schulman Syndrome (USS)

No	Patient	Year of birth	Sex	Exchange blood transfusion during newborn period	Thrombocytopenia during childhood	Plasma ADAMTS13:AC (%)	ADAMTS13 gene mutations
1	A	1999	M	+	+	< 0.5	C-Hetero
2	B	1986	F	+	+	< 0.5	Homo
3	C	1972	M	-	+	< 0.5	Homo
4	D	1978	F	+	+	< 0.5	C-Hetero
5	E	1985	M	+	+	< 0.5	C-Hetero
6	F	1993	M	+	+	0.6	C-Hetero
7	G	1987	F	+	+	< 0.5	C-Hetero
8	H	1951	M	-	-	0.6	C-Hetero
9	I	1972	M	-	+	< 0.5	C-Hetero
10	J-3	1977	F	-	+	< 0.5	C-Hetero
11	J-4	1979	M	-	+	< 0.5	C-Hetero
12	K-3	1976	F	-	+	< 0.5	C-Hetero
13	K-4	1978	F	+	+	< 0.5	C-Hetero
14	L-2	1967	F	-	-	< 0.5	C-Hetero
15	L-3	1972	F	-	+	< 0.5	C-Hetero
16	M-3	1969	F	-	-	< 0.5	C-Hetero
17	M-4	1971	F	-	-	< 0.5	C-Hetero
18	N	1986	F	+	+	< 0.5	C-Hetero
19	O-4	1958	F	-	-	< 0.5	C-Hetero
20	P	1971	M	-	+	< 0.5	C-Hetero
21	Q (1)	1983	M	+	+	< 0.5	C-Hetero
22	Q (2)	1988	M	+	+	< 0.5	C-Hetero
23	R-5	1982	F	-	+	< 0.5	C-Hetero
24	S	1982	F	-	+	0.9	⊛
25	T	1981	F	-	+	< 0.5	C-Hetero
26	U	1990	F	+	+	< 0.5	Homo
27	V	1983	F	+	+	< 0.5	C-Hetero
28	W-4	1990	F	-	+	< 0.5	C-Hetero
29	X-5	1963	F	-	-	< 0.5	⊛
30	Y	1960	F	-	+	< 0.5	C-Hetero
31	Z-3	1971	F	-	+	< 0.5	Homo
32	AA	1987	F	-	-	< 0.5	⊛
33	BB	1947	M	-	-	< 0.5	Homo
34	CC-5	2004	M	+	+	< 0.5	C-Hetero
35	DD	2007	F	-	+	< 0.5	C-Hetero
36	EE	2003	M	+	+	< 0.5	Homo
37	FF	1991	F	+	+	< 0.5	Homo
38	GG	1931	M	-	-	3.4	Homo
39	HH	2004	F	+	+	< 0.5	C-Hetero
40	II	1977	F	+	+	< 0.5	⊛
41	JJ	1977	M	-	+	< 0.5	C-Hetero

C-Hetero: Compound heterozygotes, Homo: Homozygotes, ⊛: Not determined.

Acquired TMAs

Patients with acquired TMAs are characterized by the following: 1) usually no familial occurrence, 2) presence or absence of underlying diseases or medications associated with TMAs, and 3) common sudden onset of TMA episodes during adulthood. Patients with acquired TMAs are grouped as primary (idiopathic) or secondary, and then further separated into categories as follows, based on the results of ADAMTS13: AC and ADAMTS13: INH assays.

1. Idiopathic TMAs

The patients in this group lack apparent underlying diseases or medications related to TMA episodes. Idiopathic TMAs can be further categorized into TTP and HUS subgroups. Idiopathic TTP (n=284) included two patient populations: 1) patients (n=195) with severe deficiency of ADAMTS13: AC, commonly positive for ADAMTS13: INH, and 2) patients (n=89) with clinical 'pentad' signs, regardless of plasma ADAMTS13: AC levels. Distribution of plasma ADAMTS13: AC is shown in Table 1. Detailed analysis of the clinical and laboratory features of these pa-

tients will be published elsewhere.

In contrast, idiopathic HUS (n=106) consisted of one patient population with clinical 'triad' signs, without severe deficiency of ADAMTS13: AC. Two patients of this category exhibited low levels of ADAMTS13: INH (0.5-<2 BU/mL).

2. Secondary TMAs

Secondary TMAs develop in the setting of various clinical conditions, such as infection, medication, and various underlying diseases. For instance, acquired TMAs are often associated with connective tissue diseases, and also treatment using several specific drugs. In these patients, clinical signs are often highly variable, so diagnostic differentiation of TTP or HUS appears to be insignificant.

(1) Drug-induced TMAs

A significant number of drugs have been associated with TMAs, including anti-platelet thienopyridine derivative drugs, antineoplastic drugs such as mitomycin C, and quinine (29). We have no experience with quinine-associated TMAs, but observed two suspected drug-associated TMAs:

one with sildenafil (Viagra) and the other with pegylated-interferon. Thus, drug-induced TMAs will be discussed in the following 3 subgroups.

a) Thienopyridine derivative-induced TMAs

Ticlopidine (TC) and clopidogrel (CL) are two typical thienopyridine derivatives (30). We identified 22 patients with TC-induced TMAs and one with CL-induced TMA. Nineteen of the 22 patients with TC-TMAs (86%) had severe ADAMTS13: AC deficiency and were positive for ADAMTS13: INH. The mechanism by which TC induces TMAs is still unclear, but it is speculated that TC becomes active in circulation and binds to ADAMTS13, forming a hapten-carrier complex. Antibodies formed against such a complex may be specific for the hapten, the combination hapten-carrier site, or the carrier alone, in a similar fashion to alpha-methyl dopa, which may cause the development of anti-red cell antibodies. In approximately 90% of patients with TC-induced TMAs, the onset of TMA episodes occurred within 40 days of treatment (30). The frequency of TC-induced TMAs is estimated to be one per 1,600 to 5,000 patients. In contrast, only one female patient with CL-induced TMA, who developed TMA episodes 4 days after treatment, has been reported in Japan (31). This patient had slightly reduced plasma ADAMTS13: AC (34%), and was negative for ADAMTS13: INH. The pathogenesis of CL-induced TMAs is unclear, but recent studies suggest that ADAMTS13 is released from the liver into circulation, binds to endothelial cell surfaces, and efficiently cleaves UL-VWFMs. Thus, if endothelial cell injuries are present, ADAMTS13 cannot effectively cleave UL-VWFMs; this may lead to TMA episodes. In this regard, Zakarija et al (32) recently addressed two mechanistic pathways in TMAs related to thienopyridine derivatives.

b) Mitomycin C-induced TMAs

Ten patients with mitomycin C (MMC)-induced TMAs were identified. None had severe deficiency of ADAMTS13: AC, and all were negative for ADAMTS13: INH. Previous reports (33) suggest that MMC-induced TMAs develop with a frequency of 4-15% of the patients treated with this drug. The pathophysiology of MMC-TMAs is not well understood, but it is assumed that MMC may cause vascular endothelial cell injuries.

c) TMAs associated with other drugs

We observed two other TMA patients with severe deficiency of ADAMTS13: AC and positive ADAMTS13: INH. Both of these patients were assumed to have drug-associated TMA. One patient was a 62-year-old male with chronic hepatitis C. This patient developed TMA a month after long-term treatment with pegylated-interferon; the detailed clinical course of this patient was previously reported (34). The other patient with possible drug-induced TMA was a 65-year-old male who had taken sildenafil. The patient had taken sildenafil once several months prior to development of

TMA, and then he had taken the drug twice within the 2 weeks prior to TMA. Two days after his third intake of sildenafil, the patient developed a low-grade fever, hemolytic anemia (hemoglobin 10.3 g/dL and reticulocyte 3.9%), thrombocytopenia (11,000/ μ L), and hematuria. ADAMTS13 analysis identified severe deficiency of ADAMTS13: AC (<3%) and ADAMTS13: INH positivity (1.5 Bethesda U/ mL). The patient was treated by oral administration of the anti-platelet drug dipyridamole without plasma exchange. Since then, he has recovered, and his ADAMTS13: AC returned to normal range 3 months later.

(2) Connective tissue diseases and their allied diseases (CTD/AD)-associated TMAs

A close relationship between systemic lupus erythematosus (SLE) and TTP was first described in 1939 (35). It is now known that TMAs are frequently associated with CTDs with a frequency of 1-6% of the patient population (36). We have recently reported that severe deficiency of ADAMTS13: AC and positive ADAMTS13: INH was predominantly detected in patients with rheumatoid arthritis (RA)- and SLE-associated TMAs, via the analysis of 127 patients with CTD-associated TMAs, whose samples were collected between 1998-2006 (37).

In this study, we included other miscellaneous autoimmune diseases, such as antiphospholipid syndrome (APS), as listed in Table 3, in the analysis. Thus, we examined 221 patients with CTD/AD-associated TMAs (Tables 1, 3), of whom 46 (21%) had severe deficiency of ADAMTS13: AC with positive ADAMTS13: INH, while the remaining 175 (79%) had mild-to-moderate deficiency. We presume that the high prevalence of TMA episodes in patients with CTD/AD is closely related to high plasma levels of VWF over the low levels of ADAMTS13: AC (37). Anatomical changes of the microvasculature, namely narrowed vessel cavities due to the proliferation of vascular endothelial cells, result in altered circulation hemodynamics and contribute to the formation of platelet thrombi at sites of vascular injury.

(3) Malignancy-associated TMAs

Sixty-one patients were classified into this category, which largely consisted of 2 groups: one group of patients with hematological malignancies (n=30) and the other group with malignant solid tumors (n=31) (Table 2).

Of the hematological malignancies, lymphoma was the most frequently seen (n=16), and four of the 16 patients had severe deficiency of ADAMTS13: AC with positive ADAMTS13: INH. The clinical course of one patient with intravascular lymphoma (IVL)-associated TMA was previously reported (38). In this case, the aggravation of TMA was dependent on the treatment efficacy of chemotherapy during the early stage of disease progression, but in the later stage was dependent on rituximab after several relapses during a 4-year observation period (39).

Of 31 patients with malignant solid tumor-associated TMAs, stomach cancer (n=10) was most commonly seen,

(7) TMAs associated with other causes

Forty-six TMA patients, who did not fit the aforementioned categories, were classified in this category (Table 3). Because of high heterogeneity in this category, it was sub-categorized into patients with liver diseases (n=16), those with infections (n=10), and miscellaneous causes (n=20).

We have reported that numerous liver diseases are associated with reduced plasma ADAMTS13: AC. Notably, plasma levels of ADAMTS13: AC decline in parallel to the progression of liver cirrhosis (42). More interestingly, several patients with advanced liver cirrhosis had severe deficiency of ADAMTS13: AC with positive ADAMTS13: INH. These patients were assumed to have cryptic clinical signs of TMA; therefore, the term 'subclinical TTP' was introduced. In addition, we have reported on recipients of liver transplants with early allograft dysfunction who showed severe thrombocytopenia accompanied by a marked reduction of ADAMTS13: AC one or two days after transplantation, but without any apparent clinical features of TMAs (43). This observation has been confirmed by two recent reports (44, 45), but the mechanism has not yet been addressed.

Viral or bacterial infections can trigger TMA episodes, but the mechanism has not yet been addressed. Most recently, influenza has been revisited by researchers, due to a close relationship between influenza and TMA originally reported in 1980 (46). It is now known that influenza vaccine may induce TTP or disease relapse (47). We have two patients with influenza A-associated TMAs, and one of them

had severe deficiency of ADAMTS13: AC with positive ADAMTS13: INH. Influenza virus or vaccination often worsens underlying diseases or conditions, including diabetes mellitus, pregnancy, and ongoing hemodialysis, resulting in multiorgan failure (MOF). Is it possible that such MOF is caused by microcirculatory disturbances, resembling the pathogenesis of TTP.

Human immunodeficiency virus (HIV) infection is also a known trigger of TMAs (48). In our registry, only one HIV-positive patient with severe deficiency of ADAMTS13: AC with positive ADAMTS13: INH was identified.

Finally, the TMAs that fell into the miscellaneous subcategory are too variable to address in this report. The details of some of these patients will be reported in detail elsewhere by referral physicians.

Acknowledgement

The authors thank Dr. Masahito Uemura for his critical reading and valuable comments. We also thank Ms Ayami Isonishi, and Drs. Hideo Yagi and Hiromichi Ishizashi for their excellent technical assistance performing ADAMTS13: AC assays.

Grant Support: This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan and from the Ministry of Health, Labor, and Welfare of Japan for Blood Coagulation Abnormalities (Successive Directors; Drs. Masao Nakagawa, Yasuo Ikeda, and Mitsuru Murata), and by the reward of Erwin von Bälz prize in 2008.

References

- Moake JL. Thrombotic microangiopathies. *N Engl J Med* **347**: 589-600, 2002.
- George JN. Clinical practice. Thrombotic thrombocytopenic purpura. *N Engl J Med* **354**: 1927-1935, 2006.
- Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. *Blood* **87**: 4223-4234, 1996.
- Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. *Blood* **87**: 4235-4244, 1996.
- Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. *Blood* **98**: 1654-1661, 2001.
- Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. *Blood* **98**: 1662-1666, 2001.
- Soejima K, Mimura N, Hirashima M, et al. A novel human metalloproteinase synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? *J Biochem (Tokyo)* **130**: 475-480, 2001.
- Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloproteinase involved in thrombotic thrombocytopenic purpura. *J Biol Chem* **276**: 41059-41063, 2001.
- Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. *Blood* **106**: 922-924, 2005.
- Suzuki M, Murata M, Matsubara Y, et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. *Biochem Biophys Res Commun* **313**: 212-216, 2004.
- Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. *J Thromb Haemost* **4**: 1396-1404, 2006.
- Manea M, Kristoffersson A, Schneppenheim R, et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. *Br J Haematol* **138**: 651-662, 2007.
- Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *N Engl J Med* **339**: 1578-1584, 1998.
- Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. *N Engl J Med* **339**: 1585-1594, 1998.
- Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. *Blood* **112**: 11-18, 2008.
- Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. *Br J Haematol* **88**: 816-825, 1994.
- Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH. ADAMTS 13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. *Transfusion* **49**: 206-213, 2009.

18. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. *J Clin Invest* **108**: 785-791, 2001.
19. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. *Cardiovasc Hematol Disord Drug Targets* **9**: 36-50, 2009.
20. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. *Int J Hematol* **74**: 101-108, 2001.
21. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. *Transfusion* **46**: 1444-1452, 2006.
22. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. *Transfusion* **42**: 572-580, 2002.
23. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. *Thromb Diath Haemorrh* **34**: 612, 1975.
24. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* **11**: 571-575, 2005.
25. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. *Haematologica* **92**: 95-100, 2007.
26. Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. *Am J Hematol* **51**: 255-260, 1996.
27. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. *Int J Hematol* **75**: 25-34, 2002.
28. Kokame K, Aoyama Y, Matsumoto M, Fujimura Y, Miyata T. Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. *J Thromb Haemost* **6**: 213-215, 2008.
29. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. *Curr Opin Hematol* **8**: 286-293, 2001.
30. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. *J Am Coll Cardiol* **50**: 1138-1143, 2007.
31. Fukusako T, Yamashita H, Omoto M, Matsuda K, Shinohara K, Fujimura Y. A case of thrombotic thrombocytopenic purpura associated with clopidogrel. *Clin Neurol* **47**: 635-638, 2007.
32. Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). *Kidney Int* **75** (Suppl 112): S20-S24, 2009.
33. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. *Semin Thromb Hemost* **31**: 681-690, 2005.
34. Kitano K, Gibo Y, Kamijo A, et al. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. *Haematologica* **91**: ECR34, 2006.
35. Gitlow S, Goldmark C. Generalized capillary and arteriolar thrombosis. Report of two cases with a discussion of the literature. *Ann Intern Med* **13**: 1046-1067, 1939.
36. Sato T, Hanaoka R, Ohshima M, et al. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital. *Clin Exp Rheumatol* **24**: 454-455, 2006.
37. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. *Thrombosis and Haemostasis* **102**: 371-378, 2009.
38. Kawahara M, Kanno M, Matsumoto M, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. *Neurology* **63**: 1731-1733, 2004.
39. Kanno M, Nakamura S, Kawahara M, et al. Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab. *Int J Hematol* **88**: 345-347, 2008.
40. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. *Blood* **93**: 3798-3802, 1999.
41. Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. *Br J Haematol* **144**: 742-754, 2009.
42. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. *Thromb Haemost* **99**: 1019-1029, 2008.
43. Ko S, Okano E, Kanehiro H, et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. *Liver Transpl* **12**: 859-869, 2006.
44. Kobayashi T, Wada H, Usui M, et al. Decreased ADAMTS13 levels in patients after living donor liver transplantation. *Thromb Res* **124**: 541-545, 2009.
45. Pereboom IT, Adelmeijer J, van Leeuwen Y, Hendriks HG, Porte RJ, Lisman T. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. *Am J Transplant* **9**: 1189-1196, 2009.
46. Wasserstein A, Hill G, Goldfarb S, Goldberg M. Recurrent thrombotic thrombocytopenic purpura after viral infection. Clinical and histologic simulation of chronic glomerulonephritis. *Arch Intern Med* **141**: 685-687, 1981.
47. Dias PJ, Gopal S. Refractory thrombotic thrombocytopenic purpura following influenza vaccination. *Anaesthesia* **64**: 444-446, 2009.
48. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). *Medicine (Baltimore)* **76**: 369-380, 1997.

A 9-MONTH-OLD INFANT WITH ACQUIRED IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA CAUSED BY INHIBITORY IgG-AUTOANTIBODY TO ADAMTS13

Atsushi Sato, MD, PhD, Yoshiyuki Hoshi, MD, PhD, and Masaei Onuma, MD

□ *Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan*

Ryusuke Sato, MD, PhD □ *Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan*

Yukiko Tsunematsu, MD, PhD □ *Department of Strategic Medicine, Division of Pediatric Oncology, National Center for Child Health and Development, Tokyo, Japan*

Ayami Isonishi, BS, Masanori Matsumoto, MD, PhD, and Yoshihiro Fujimura, MD, PhD □ *Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan*

Masue Imaizumi, MD, PhD □ *Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan*

□ *Although acquired idiopathic thrombotic thrombocytopenic purpura (ai-TTP) is rare in children, the authors present the case of a 9-month-old boy with ai-TTP showing severe deficiency of ADAMTS13 activity by its inhibitory IgG-autoantibody (4.8 Bethesda units/mL). Plasma exchange therapy was clinically effective but transient. Deficient activity of ADAMTS13 with the presence of its inhibitor persisted for 7 months after the initial diagnosis. However, other laboratory findings improved gradually with steroid (pulse) therapy. The hitherto insufficiently characterized clinical settings of ai-TTP during early childhood underscore the importance of measuring ADAMTS13 activity and its inhibitors for differential diagnosis in patients with thrombocytopenia of unknown etiology.*

Keywords acquired TTP, ADAMTS13, infancy, von Willebrand factor-cleaving protease

Thrombotic thrombocytopenic purpura (TTP) is prominent in disorders with thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and organ dysfunctions such as neurological

Received 1 December 2008; Accepted 9 October 2009.

Address correspondence to Atsushi Sato, MD, Department of Hematology and Oncology, Miyagi Children's Hospital, Aoba-ku, Sendai 989-3126, Japan. E-mail: asatoh@miyagi-children.or.jp

abnormalities or renal insufficiency. Recent reports have described that von Willebrand factor (vWF) cleaving protease, designated as ADAMTS13, plays important roles in TTP pathophysiology. The lack of ADAMTS13 activity causes the accumulation of unusually large vWF multimers in the plasma, resulting in the disseminated platelet thrombi characteristic of TTP [1, 2]. Previous reports described that 18–72% of clinically diagnosed TTP patients had severe deficiency of ADAMTS13 activity [3].

Decreased activity of ADAMTS13 in patients with TTP might be associated with either inherited or acquired mechanisms. Hereditary TTP, known as Upshaw–Schulman syndrome (USS), results from ADAMTS13 gene mutations [4, 5]. In contrast, acquired TTP—either idiopathic or secondary to drugs, pregnancy, or diseases such as infections, cancers, and autoimmune diseases—is caused mostly by autoantibody against ADAMTS13 [6, 7].

While approximately one-third of USS cases with an inherent deficiency of ADAMTS13 are diagnosed in adolescence or adulthood after passing early childhood [8], acquired TTP in children, including infant patients, has been reported in the relevant literature. This report describes a young infant with acquired idiopathic TTP caused by IgG autoantibody against ADAMTS13. Clinical findings for this patient suggest that assays of ADAMTS13 activity and its inhibitor are indispensable for differential diagnosis with USS and other thrombocytopenic diseases during childhood.

CASE REPORT

In January 2005, a 9-month-old boy with petechial hemorrhage was referred to the Tokyo Medical and Dental University Hospital for suspected idiopathic thrombocytopenic purpura (ITP). He showed nonimmune hemolytic anemia as well as thrombocytopenia. Subsequent examinations revealed that his plasma ADMATS13 activity by vWF multimer assay [6] was markedly decreased (<3%). Moreover, inhibitor activity was detected in the titer of 4.8 BU/mL. This inhibitor activity resided on the purified IgG (data not shown). Based on these findings, he was diagnosed as having acquired idiopathic TTP. Treatment with plasma exchange (PE) performed at the National Center for Child Health and Development was effective to decrease the inhibitor activity (0.2 BU/mL) and increase the serum ADAMTS13 activity to 62.8%, engendering the improvement of his anemia and thrombocytopenia. However, this effect of 6 courses of PE was transient: after about 1 month, the inhibitor activity rebounded to the higher titer at 10 BU/mL with recurrence of low ADAMTS13 activity (<3%) and hematological abnormalities. No effect of administration of fresh frozen plasma (FFP) was observed, nor any obvious sign of renal insufficiency. After PE treatment, as his platelet count decreased rapidly to the critical level lower than $10 \times 10^9/L$, presenting the increased risk of hemorrhage, attending

physicians chose to administer low doses of continuous platelet infusion under close observation and started treatment with oral prednisolone (PSL) (2 mg/kg/day). His platelet counts were constantly higher than $1.0 \times 10^9/L$ after beginning these treatments.

At admission to our hospital in March 2005, he had no petechiae, hepatomegaly, or neurological abnormality. His mental status was normal. His peripheral blood examination showed severe thrombocytopenia ($1.6 \times 10^9/L$), mild anemia (Hb 7.9 g/dL), and elevation of reticulocyte counts (16.1%). In fact, RBC fragmentation was found in his peripheral blood smear (0.16%). Biochemical examination revealed mild elevation of lactate dehydrogenase (672 IU/L) and indirect bilirubin (0.88 mg/dL), in addition to decreased haptoglobin: lower than 10 mg/dL. Both blood urea nitrogen (14.2 mg/dL) and serum creatinine (0.19 mg/dL) values were within normal ranges. Results of both direct and indirect Coombs tests were negative. Hemostatic examination showed that PT, APTT, and FDP were within normal ranges, but a slightly elevated value of D-dimer was observed. *Escherichia coli* O157 was not detected in his stool culture. His ADAMTS13 activity remained at an undetectable level (<3%). Furthermore, the inhibitor of ADAMTS13 was detected in serum with the titer of 4.3 BU/mL. Moreover, ADAMTS13 gene analysis in this patient revealed no disease-causing mutations for USS (data not shown).

During his stay at our hospital, he received pulse therapy using methylprednisolone (mPSL) (30 mg/kg/day for 3 days). Although the effect of this therapy was not apparent initially, platelet counts of his peripheral blood increased gradually over the 7 weeks subsequent to pulse therapy. Thereafter, the recovery of ADAMTS13 activity with a concomitant disappearance of its inhibitory activity was observed after approximately 5 and 7 months, respectively, following pulse therapy and initial treatment (Figure 1). Oral PSL was stopped when the recovery of ADAMTS13 activity was detected.

DISCUSSION

We report here an infant case with acquired TTP caused by anti-ADAMTS13 autoantibody. Based on findings of low ADAMTS13 activity with serum inhibitors, our patient was considered to have an acquired form of TTP. Only 2 cases diagnosed as acquired TTP during the first year of life have been reported in the relevant literature [9, 10] (Table 1). Ashida et al. reported a 9-month-old girl with high titer of ADMAMTS13 inhibitor (200 Bethesda units/mL), who was treated successfully with mPSL pulse therapy following PE. Schneppenheim et al. also reported an 11-month-old boy with recurrent thrombocytopenia who responded to corticosteroids. For our patient, however, we were unable to conclude simply that steroid therapy was effective because low ADAMTS13 activity with inhibitors was sustained for a certain time after hematological improvement was achieved.




FIGURE 1 Clinical course of the present case of acquired TTP in infancy. ADAMTS13 activity and its autoantibodies were examined using frozen plasma stocked in -80°C with sensitive chromogenic ADAMTS13-act-ELISA method described in a prior study [16]. Abbreviations: PSL, prednisolone; FFP, fresh frozen plasma; INH, inhibitors; BU, Bethesda unit.

Neurological abnormalities and renal insufficiency are the hallmarks of acquired TTP in adults. These symptoms are worsened by platelet transfusions through expanding thrombus formation [11]. However, our patient, with a low titer of antibodies, showed no such symptoms at onset or

TABLE 1. Infants with acquired TTP showing anti-ADAMTS13 autoantibody

Patient no.	Sex	Age (months)	Renal impairment	CNS complication	Initial diagnosis	ADAMTS13		Ref.
						activity (%)	Inhibitor (BU/mL)	
1	F	9	Hematuria	Hemiconvulsion	TTP	<3	200	[9]
2	M	11	(-)	(-)	ITP	<2	(+)	[10]
Present case	M	9	(-)	(-)	ITP	<3	4.8	

Note. M, male; F, female; CNS, central nervous system; ITP, idiopathic thrombocytopenic purpura; TTP, thrombotic thrombocytopenic purpura; BU, Bethesda unit.

worsening in the hospital. In contrast, an infant TTP with high titer of antibodies showed both neurological and renal symptoms [9]. Results show that clinical symptoms become more severe in patients with high titer of inhibitor [12]. Therefore, results suggest that the titer of inhibitors might be a critical factor determining the severity of clinical manifestations of acquired TTP in infancy.

It is noteworthy that, during approximately 3 months, our patient showed hematological improvement despite the sustained low ADAMTS13 activity and the presence of inhibitor, thereby indicating that low ADAMTS13 activity does not necessarily worsen thrombotic microangiopathy. This finding in our patient might resemble the clinical picture of a subset of patients with USS who might be asymptomatic during infancy despite the inherent impairment of ADAMTS13 function [8, 13].

The classical 'pentad' of TTP is known to be fully present in only a minority of patients [3], indicating a limitation of diagnosis based solely on symptoms and routine examinations. Childhood TTP might be diagnosed initially as hemolytic anemia, Evans syndrome, or ITP [10, 14]; the assessment of ADAMTS13 would be of value for differential diagnosis of these diseases. Recently, rapid assays for measuring ADAMTS13 activity have been developed [15, 16]. Therefore, the assessment of ADAMTS13 activity and its inhibitor would be of value as routine laboratory tests for differential diagnosis of thrombocytopenia of unknown etiology during childhood.

ACKNOWLEDGMENT

This work was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology and from the Ministry of Health, Labor and Welfare of Japan.

Declaration of Interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES

- [1] Fujimura Y, Matsumoto M, Yagi H, et al. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. *Int J Hematol*. 2002;75:25–34.
- [2] Loirat C, Girma JP, Desconclois C, et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. *Pediatr Nephrol*. 2008;24:Epub.
- [3] Mannucci PM, Peyvandi F. TTP and ADAMTS13: When is testing appropriate? *Hematol Am Soc Hematol Educ Program*. 2007;121–126.
- [4] Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature*. 2001;413:488–494.
- [5] Shibagaki Y, Matsumoto M, Kokame K, et al. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. *Nephrol Dial Transplant*. 2006;21:1289–1292.
- [6] Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *N Engl J Med*. 1998;339:1578–1584.
- [7] Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. *Hematol Am Soc Hematol Educ Program*. 2004;407–423.
- [8] Loirat C, Veyradier A, Girma JP, et al. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. *Semin Thromb Hemost*. 2006;32:90–97.
- [9] Ashida A, Nakamura H, Yoden A, et al. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. *Am J Hematol*. 2002;71:318–322.
- [10] Schneppenheim R, Budde U, Hassenpflug W, et al. Severe ADAMTS-13 deficiency in childhood. *Semin Hematol*. 2004;41:83–89.
- [11] Fontana S, Kremer Hovinga JA, Lammle B, et al. Treatment of thrombotic thrombocytopenic purpura. *Vox Sang*. 2006;90:245–254.
- [12] Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. *Clin Lab*. 2001;47:387–392.
- [13] Tsai H-M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. *Hematol Oncol Clin North Am*. 2007;21:609–632.
- [14] Horton TM, Stone JD, Yee D, et al. Case series of thrombotic thrombocytopenic purpura in children and adolescents. *J Pediatr Hematol Oncol*. 2003;25:336–339.
- [15] Kokame K, Kokubo Y, Okayama A, et al. FRETTS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. *Br J Haematol*. 2005;129:93–100.
- [16] Kato S, Matsumoto M, Matsuyama T, et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. *Transfusion*. 2006;46:1444–1452.

Pivotal role of ADAMTS13 function in liver diseases

Masahito Uemura · Yoshihiro Fujimura · Saiho Ko ·
Masanori Matsumoto · Yoshiyuki Nakajima ·
Hirosi Fukui

Received: 1 July 2009 / Revised: 17 December 2009 / Accepted: 21 December 2009 / Published online: 7 January 2010
© The Japanese Society of Hematology 2010

Abstract The liver is a major source of clotting and fibrinolytic proteins, and plays a central role in thromboregulation. Patients with advanced liver diseases tend to bleed because of reduced plasma levels of several clotting factors and thrombocytopenia, but they do also exhibit thrombotic complications. ADAMTS13 is a metalloproteinase, produced exclusively in hepatic stellate cells, and specifically cleaves highly multimeric von Willebrand factor (VWF). VWF plays a pivotal role in hemostasis and thrombosis, and its function is dependent on its multimeric state. Deficiency of ADAMTS13 results in accumulation of unusually large VWF multimers (UL-VWFM) in plasma, in turn induces platelet clumping or thrombi under high shear stress, followed by microcirculatory disturbances. Considering that UL-VWFM, the substrate of ADAMTS13, is produced in transformed vascular endothelial cells at sites of liver injury, decreased ADAMTS13 activity may be involved in not only sinusoidal microcirculatory disturbances, but also subsequent progression of liver injuries, eventually leading to multiorgan failure. This concept can be applied to the development or aggravation of liver diseases, including liver cirrhosis, alcoholic hepatitis,

veno-occlusive disease, and adverse events after liver transplantation. These results promise to bring further understanding of the pathophysiology of liver diseases, and offer new insight for development of therapeutic strategies.

Keywords ADAMTS13 · Von Willebrand factor · Liver cirrhosis · Alcoholic hepatitis · Veno-occlusive disease · Liver transplantation · Microcirculatory disturbance · Multiorgan failure

1 Introduction

The liver plays a central role in hemostasis by synthesizing clotting factors, coagulation inhibitors, and fibrinolytic proteins [1]. The hemostatic system is normally in a delicate balance between pro-hemostatic and anti-hemostatic processes [1]. Severe liver diseases are accompanied by multiple changes in the hemostatic system, and the alterations in the system may lead to either a bleeding or thrombosis [1, 2]. Bleeding is clinically evident but hypercoagulability is also an important role in many aspects including poor hepatic blood flow, vasculopathy, and portal and hepatic vein thrombosis, which are closely related to microcirculatory disturbance [2]. Deficiency of anticoagulant proteins and high levels of several procoagulant factors may favor hypercoagulability [2], but the mechanisms underlying this disorder have not been fully elucidated.

ADAMTS13 (*a* disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF) between Tyr1605 and Met1606 within its A2 domain [3, 4]. ADAMTS13 deficiency, caused either by mutations in the *ADAMTS13* gene [3–6] or by inhibitory

M. Uemura and Y. Fujimura contributed equally to this study.

M. Uemura (✉) · H. Fukui
Third Department of Internal Medicine, Nara Medical
University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
e-mail: muemura@naramed-u.ac.jp

Y. Fujimura · M. Matsumoto
Department of Blood Transfusion Medicine,
Nara Medical University, Kashihara, Nara 634-8522, Japan

S. Ko · Y. Nakajima
Department of Surgery, Nara Medical University,
Kashihara, Nara 634-8522, Japan

autoantibodies against ADAMTS13 [7, 8], results in the accumulation of “unusually large” VWF multimers (UL-VWFM) in plasma; this, in turn, leads to platelet clumping and/or thrombi under high shear stress and subsequent microcirculatory disturbances.

In 2000, we reported that predominantly decreased ADAMTS13 activity (ADAMTS13:AC) in sick children with advanced cirrhotic biliary atresia could be fully restored after living donor liver transplantation, indicating that the liver is the major organ producing ADAMTS13 [9]. In 2001, three other groups indicated that ADAMTS13 mRNA was exclusively expressed in the liver by northern blot analysis [5, 10, 11]. Subsequently, we were able to demonstrate that ADAMTS13 was produced exclusively in hepatic stellate cells (HSCs) using both *in situ* hybridization and immunohistochemistry [12]. Platelets [13], vascular endothelial cells [14], and kidney podocytes [15] were also shown to be ADAMTS13-producing cells, but the relevance to the pathogenesis of thrombo-regulation in each organ remained unclear.

Since HSCs are the major ADAMTS13-producing cells in human liver [12], we will review the potential functional role of ADAMTS13 in association with the pathogenesis of liver diseases.

2 Hepatic microcirculation and hypercoagulability in liver diseases

Hepatic microcirculation comprises a unique system of capillaries, called sinusoids, which are lined by three different cell types: sinusoidal endothelial cells (SEC), HSC, and Kupffer cells [16]. The SEC modulates microcirculation between hepatocytes and the sinusoidal space through the sinusoidal endothelial fenestration. The SEC has tremendous endocytic capacity, including for VWF and the extracellular matrix, and secretes many vasoactive substances [16]. The HSC is located in the space of Disse adjacent to the SEC, and regulates sinusoidal blood flow by contraction or relaxation induced by vasoactive substances [17]. Kupffer cells are intrasinusoidally located in tissue macrophages, and secrete potent inflammatory mediators during the early phase of liver inflammation [16]. Intimate cell to cell interaction has been found between these sinusoidal cells and hepatocytes [16, 17].

Vascular endothelial cells play a pivotal role in hemostasis and thrombosis [3, 4]. VWF is a marker of endothelial cell activation (damage), and plays an essential role in hemostasis [3, 4]. In the normal state, VWF immunostaining is usually positive in large vessels, but negative in the SEC [18]. On the occurrence of liver injury accompanied by a necroinflammatory process, the SEC becomes positive for VWF, presumably in association with

the capillarization of hepatic sinusoids [19]. Subsequently, platelets adhere to subendothelial tissue mediated by UL-VWFM [3, 4]. ADAMTS13 then cleaves UL-VWFM into smaller VWF multimers [3, 4]. This interaction of ADAMTS13 and UL-VWFM is, indeed, the initial step in hemostasis [3, 4]. Recent work has further shown that recombinant ADAMTS13 binds to recombinant CD36 and platelet membrane CD36 *in vitro*, demonstrating a role for this protein in localizing ADAMTS13 to endothelial cells expressing CD36, where ADAMTS13 regulates the cleavage of VWF [20].

In patients with fulminant hepatic failure and liver cirrhosis, circulating plasma VWF antigen (VWF:AG) levels are extremely high [21–23]. Many fibrin thrombi were found in the hepatic sinusoids in acute liver failure, suggesting a role for intravascular coagulation in the pathogenesis of hepatic necrosis [24]. In cirrhotic liver tissue [25] and even tissue from patients in early stages of alcoholic liver diseases [26], VWF immunostaining shows positive cells predominantly at the scar–parenchyma interface, within the septum, and in the sinusoidal lining. Portal or hepatic vein thrombosis is often observed in advanced cirrhosis [27, 28] and microthrombi formation was found in one or multiple organs in half of autopsied cirrhotics [29]. This hypercoagulable state in liver diseases may be involved in hepatic parenchymal extinction, the acceleration of liver fibrosis, and disease progression.

Considering that ADAMTS13 is synthesized in HSC [12] and its substrate, UL-VWFM, is produced in transformed SEC during liver injury [18], decreased plasma ADAMTS13:AC may involve not only sinusoidal microcirculatory disturbances, but also subsequent progression of liver diseases, eventually leading to multiorgan failure. Based on these findings, it is of particular interest to evaluate plasma ADAMTS13:AC in liver disease patients.

3 ADAMTS13 assays

The classic VWF multimer assay used to be the gold standard method for evaluating plasma ADAMTS13:AC; however, its major disadvantage was that it took several days to provide results [7]. In this regard, the discovery of a minimum 73 amino acid residue sequence within the VWF-A2 domain (VWF73) by Kokame et al. [30], which was prerequisite for the rapid cleavage by ADAMTS13, provided a breakthrough in developing novel methods to assay ADAMTS13:AC. Indeed, a convenient fluorescence method based on FRET-VWF73 is now widely used as the gold standard second generation method [31]. However, the sensitivity of FRET-VWF73 remains approximately 3% of the normal control, and the presence of hemoglobin, bilirubin, and/or chylomicron in samples significantly

influences the results [32]. To solve these problems, a unique method for determining ADAMTS13:AC, termed ADAMTS13-act-ELISA, was developed in our laboratory as a third generation method [33]. This assay was established after production of a novel murine monoclonal antibody to ADAMTS13, termed N-10, which specifically recognizes the Y1605 residue of the VWF-A2 domain, generated by ADAMTS13 cleavage [33]. The lower limit of this assay is 0.5% of the normal control. Developing an automated more rapid assay for ADAMTS13:AC and its usage in hospitals is urged to prevent unnecessary or harmful infusions of platelet concentrates to patients with masked thrombocytopenia, such as “subclinical TTP”.

4 The physiological significance of ADAMTS13 in liver diseases

4.1 Liver cirrhosis

Sinusoidal microcirculatory disturbance in liver cirrhosis occurs when the normal hepatic structure is disrupted by fibrin deposition [19] or by impaired balance between the action of vasoconstrictors and vasodilators in hepatic vascular circulation [16]. Studies have shown that cirrhotic liver exhibits a hyperresponse to vasoconstrictors, including catecholamine, endothelin, and leukotrienes D₄ [16]. Now it is well-accepted that thrombocytopenia gradually progresses as functional liver capacity decreases (Fig. 1a). Previously, thrombocytopenia in liver cirrhosis has been speculated to be associated with hypersplenism [34] and decreased synthesis of thrombopoietin in the affected liver [35]. Our recent studies, however, have provided evidence considering that UL-VWFM accumulated in plasmas with far advanced cirrhotic patients enhances high shear-stress-induced platelet aggregation, resulting in thrombocytopenia [36].

Mannucci et al. [37] originally reported a significant reduction of plasma ADAMTS13:AC in advanced cirrhotics. Recently, we showed that ADAMTS13:AC decreased with increasing severity of cirrhosis [36] (Fig. 1b). The values determined by act-ELISA correlated well with those of the classical VWFM assay, and also closely correlated with ADAMTS13 antigen determined by the antigen-ELISA. These results confirmed that both ADAMTS13 activity and antigen decreased with increasing cirrhosis severity [36] (Fig. 1b, c). Our results are consistent with findings described by Feys et al. [38]. In sharp contrast, Lisman et al. [39] showed that both ADAMTS13 activity and antigen levels were highly variable; however, they did not distinguish between patients with varying degrees of cirrhosis. It is unclear why Lisman et al. reached the conclusions different from ours. One possible explanation relates to two distinct clinical settings: a majority of our




Fig. 1 Platelet counts and plasma levels of ADAMTS13:AC and ADAMTS13:AG in patients with chronic liver diseases. Platelet count decreased with the severity of chronic liver diseases, but no difference was found between Child B and C (a). Plasma ADAMTS13:AC determined by the ELISA progressively decreased with worsening cirrhosis (b). Severe deficiency in ADAMTS13:AC (<3%) was seen in five liver cirrhosis patients with Child C by the VWFM assay, but by the act-ELISA they ranged from <0.5 to 15.9% of the normal control (b, shown by arrows). The ADAMTS13:AG levels determined by ELISA also decreased with increasing cirrhosis severity (c), which highly correlated with ADAMTS13:AC measured by the act-ELISA ($r = 0.715$, $p < 0.001$). Open circles normal controls, open triangles chronic hepatitis, open squares cirrhosis with Child A, closed triangles cirrhosis with Child B, closed circles cirrhosis with Child C. Shaded area shows normal range. ADAMTS13:AC ADAMTS13 activity, ADAMTS13:AG ADAMTS13 antigen. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ significantly different between the two groups (partially modified from [36])

patients developed cirrhosis secondary to HCV infection, whereas in the study of Lisman et al. a half of the patients suffered from alcohol abuse-related cirrhosis. Further, the techniques used to determine ADAMTS13:AC differed between our study and theirs. It is assumed that the collagen-binding assay they used can be highly influenced by the increased amount of VWF:Ag in tested cirrhotic plasmas [38], because the substrate in this assay is intact multimeric VWF. In this regard, our act-ELISA is performed using VWF73-based fusion protein, termed GST-VWF73-His, which is readily cleaved by ADAMTS13

without any protein denaturant, and therefore the increased amount of VWF:Ag in tested plasmas does not interfere the assays [36].

Obviously, plasma levels of VWF:Ag substantially increase as liver diseases progress (Fig. 2a) [36], as previously indicated [22, 23]. This is presumably attributed to sinusoidal and/or extrahepatic endothelial damage induced by endotoxin and cytokines [22, 23, 40, 41]. The VWF:RCo was higher (Fig. 2b) [36], but the ratio of VWF:RCo/VWF:Ag was lower in cirrhotic patients than in healthy subjects, suggesting that increased VWF:Ag appears less functional in cirrhosis patients [39]. Nevertheless, our study has clearly shown that the ratio of VWF:RCo/ADAMTS13:AC progressively increases with the worsening of chronic liver diseases (Fig. 2c), more strengthening an enhanced thrombogenesis with the progresses of liver dysfunction and thrombocytopenia [36]. As a part of reflection in our scenario, the decreased platelet counts paralleled to the plasma levels of ADAMTS13:AC [36].

Regarding VWF multimers, the higher molecular weight multimer showed greater degradation than in healthy controls, thus maintaining normal enzyme-to-substrate (ADAMTS13/UL-VWFMs) ratio to maintain blood fluidity [39]. Our recent study showed that there were three different VWFm patterns in cirrhotic patients with lower ADAMTS13:AC (<50% of controls): normal-VWFm was detected in 53%, degraded-VWFm in 31%, and UL-VWFm in 16% (Fig. 3) [36]. UL-VWFm-positive patients showed the lowest ADAMTS13:AC, and the highest values of serum creatinine, blood urea nitrogen, and blood ammonia. In addition, cirrhotic patients with UL- and normal-VWFm had higher levels of VWF:RCo and Child-Pugh score, and lower values of cholinesterase and hemoglobin than those with degraded-VWFm [36]. The pattern, therefore, appears to shift from degraded- to normal-VWFm, and finally to UL-VWFm as functional liver capacity and renal function deteriorate, indicating that advanced cirrhosis may be a predisposing state toward platelet microthrombi formation, even in the absence of clinically overt thrombotic events [36]. In fact, portal or hepatic vein thrombosis is often observed in advanced liver cirrhosis patients routinely screened with Doppler ultrasound [27] and in cirrhotic liver tissue removed at transplantation [28] and at autopsy [29], consistent with our hypothesis.

The mechanism responsible for the decrease in ADAMTS13:AC in advanced cirrhotics may include enhanced consumption due to the degradation of large quantities of VWF:AG [37], inflammatory cytokines [42, 43], and/or ADAMTS13 plasma inhibitor [7, 8]. It is controversial whether ADAMTS13 deficiency is caused by decreased production in the liver; Kume et al. [44] reported that HSC apoptosis plays an essential role in decreased




Fig. 2 Plasma levels of VWF:Ag, VWF:RCo, and VWF:RCo/ADAMTS13:AC ratio in patients with chronic liver disease. The VWF:Ag increased with the progression of chronic liver diseases, but the difference between Child B and C did not reach statistical significance (a). The VWF:RCo is higher in liver cirrhosis patients than in patients with chronic hepatitis and healthy subjects, but it did not differ among subgroups within liver cirrhosis (b). The VWF:RCo relative to ADAMTS13:AC progressively increased with worsening chronic liver disease (c). VWF:Ag von Willebrand factor antigen, VWF:RCo von Willebrand factor ristocetin cofactor activity, ADAMTS13:AC ADAMTS13 activity. Shaded area shows normal range. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ significantly different between the two groups (partially modified from [36])

ADAMTS13:AC using dimethylnitrosamine-treated rats, but not carbon tetrachloride (CCl_4)-treated animals, whereas Niiya et al. [45] found up-regulation of ADAMTS13 antigen and proteolytic activity in liver tissue using rats with CCl_4 -induced liver fibrosis. We observed the inhibitor of ADAMTS13 in 83% of patients with severe to moderate ADAMTS13 deficiency, but its inhibitory activity was in a marginal zone between 0.5 and 1.0 BU/ml in most cases except a TTP patient (2.0 BU/ml) and a patient with severe ADAMTS13 deficiency (3.0 BU/ml) [36]. Interestingly, IgG-type autoantibodies specific to purified plasma derived-ADAMTS13 were detected by western blotting only in five end-stage cirrhotics with severe ADAMTS13 deficiency (<3%) corresponding to TTP [36]. One patient showed an apparent TTP [46], while the other




Fig. 3 Plasma VWF multimer in 49 liver cirrhosis patients with severe to mild deficiency of ADAMTS13:AC. The VWF multimer was analyzed by a vertical SDS–1.0% agarose gel electrophoresis system. Five patients (patients no. 1–5) were originally identified as a severe deficiency of plasma ADAMTS13:AC by the von Willebrand factor multimer (VWFm) assay. Twenty-two patients (patients no. 6–27) showed a moderate deficiency (3–25% of the control), and remaining 22 patients (no. 28–49) mild deficiency (25–50% of the control) of plasma ADAMTS13:AC by both methods of VWFm assay

and the act-ELISA, without discordant results. There were three different patterns including degraded-, normal-, and UL-VWFm. Out of these 49 patients, 26 (53.1%) showed normal VWFms, 15 (30.6%) degraded-VWFms, and the remaining eight (patients no. 3, 4, 11, 14, 16, 18, 23, and 26) (16.3%) UL-VWFms. ADAMTS13 activity, VWFm von Willebrand factor multimer, UL-VWFm unusually large von Willebrand factor multimer, NP normal control plasma (partially modified from [36])

four cirrhotics did not show apparent clinical features of TTP, but had complications of hepatorenal syndrome (HRS), spontaneous bacterial peritonitis (SBP), marked inflammation together with cytokinemia, and advanced hepatocellular carcinoma (HCC) [36]. Various clinical conditions, including infection, malignancies, and certain drugs, can lead to acquired TTP [47]. In advanced cirrhotics, endotoxemia is frequently detected [23], and SBP sometimes occurs [48]. HCC is highly complicated as the cirrhotic stage progresses [49], suggesting a high-risk state of platelet microthrombi formation. Some end-stage cirrhotics who have extremely low ADAMTS13:AC as well as its IgG inhibitor might be under conditions similar to TTP, or might reflect “subclinical TTP” [36].

With respect to the autoantibodies in patients with HCV-associated liver diseases, there is a general consensus that the overall prevalence of serum non-organ-specific autoantibodies is significantly higher in patients with HCV (about one-third of all cases) than in both healthy subjects and patients with HBV [50–52], but not alcoholic liver injury. That might be additional reason why ADAMTS13:AC significantly decreased in our most patients with HCV-related cirrhosis, but its activity seemed to be highly variable in most patients with alcohol abuse-related cirrhosis as shown by Lisman et al. [39]. Indeed, of our five end-stage LC patients with IgG-type autoantibodies, two were related to HCV, and each one to HBV, PBC and cryptogenic, but none of patients with alcohol abuse-related cirrhosis were found. Further studies will be necessary to clarify whether inhibitors other than the IgG inhibitor might be involved in cirrhotics with lower ADAMTS13:AC.

4.2 Alcoholic hepatitis (AH)

In alcoholic liver diseases, sinusoidal microcirculatory disturbance is thought to play an important pathogenic role [53, 54]. This includes narrowing of the sinusoidal space due to ballooned hepatocytes and perisinusoidal fibrosis, imbalances between endothelin and nitric oxide, and contraction of HSC [53, 54]. AH is a potentially life-threatening complication of alcohol abuse. The severe form of AH, severe alcoholic hepatitis (SAH), is characterized by multiorgan failure with manifestations of acute hepatic failure [55, 56]. In the pathogenesis of SAH, endotoxemia due to hepatic reticuloendothelial dysfunction and increased intestinal permeability may trigger enhanced proinflammatory cytokine production, which potentially causes systemic inflammatory response syndrome together with microcirculatory disturbances, and subsequent multiorgan failure [55, 56].

In our study, plasma ADAMTS13:AC was markedly decreased in the non-survivors of SAH with multiorgan failure; in contrast, mild to moderate decrease was observed in survivors of SAH and those with AH [57]. The VWF:AG was remarkably high in the non-survivors of SAH [58]. At the recovery stage, ADAMTS13:AC returned to the normal range, and the VWF:AG decreased in the survivors, whereas in a non-survivor with SAH, ADAMTS13:AC remained extremely low, and the VWF:AG was still high [57, 58]. UL-VWFm was detected in four of five SAH patients and in five of nine AH patients [58]. The findings of enhanced UL-VWFm production and deficient ADAMTS13:AC may, in part, contribute not only to the development of multiorgan failure but also to the

progression of liver injury through microcirculatory disturbances [57, 58].

Potential mechanism for decreased ADAMTS13:AC may include cytokinemia [42, 43, 59], endotoxemia [59, 60], the inhibitor of ADAMTS13 [7, 8, 59], and the consumption of the protease [37]. Recent investigations demonstrated that IL-6 inhibited the action of ADAMTS13 under flow conditions, and both IL-8 and TNF- α stimulated the release of UL-VWFM in human umbilical vein endothelial cells *in vitro* [42]. It remains to be clarified whether the IL-6 directly would hamper the cleavage of UL-VWFM or IL-6 would down-regulate gene expression of ADAMTS13 with modifying the promoter activity. IFN- γ , IL-4, and TNF- α also inhibit ADAMTS13 synthesis and activity in rat primary HSC [43]. In addition, inflammation-associated ADAMTS13 deficiency promotes formation of UL-VWFM [61], and intravenous infusion of endotoxin to healthy volunteers caused a decrease in plasma ADAMTS13:AC together with the appearance of UL-VWFM [60]. From these results as well as our own, marked endotoxemia may be closely related to decreased ADAMTS13:AC and the appearance of UL-VWFM through enhanced cytokinemia in AH patients [59]. It will be necessary to clarify what types of inhibitor may be involved in the association with inflammatory cytokines and endotoxin.

4.3 Hepatic veno-occlusive disease (VOD)

Hepatic VOD is a life-threatening complication of patients undergoing allogeneic stem cell transplantation (SCT), and occurs at frequencies of 1–54% [62, 63]. Clinically, hepatic VOD is characterized by hyperbilirubinemia, painful hepatomegaly, and fluid retention [63]. Histologically, VOD features sinusoidal fibrosis, necrosis of pericentral hepatocytes, and consequent narrowing of central veins [62, 63]. In these patients, the SEC is the primary site of toxic injury caused by chemotherapy and/or radiation in the setting of SCT, and this initial insult may ultimately lead to the circulatory compromise of centrilobular hepatocytes [62, 63].

Our recent study demonstrated that plasma ADAMTS13:AC is reduced in hepatic VOD patients after SCT (12–32% of normal) compared to non-VOD patients (57–78% of normal), even before any conditioning regimen and throughout SCT, and that the activity might thus be a predictor for the development of hepatic VOD [64]. A multicenter, prospective, randomized controlled study revealed that prophylactic fresh frozen plasma (FFP) infusion as a source of ADAMTS13 may be instrumental in preventing the development of hepatic VOD after SCT [65]. In two typical cases with hepatic VOD, plasma levels of VWF:AG progressively increased and ADAMTS13:AC gradually decreased from preconditioning or the early

period after the SCT to the later period at the occurrence of hepatic VOD [65].

Interestingly, in VOD patients, VWFM corresponding to high and intermediate molecular weight, which is usually seen in normal plasma, were lacking at preconditioning or the early period after SCT, and thereafter gradually appeared [65]. Furthermore, in the group without prophylactic FFP infusion, high and/or intermediate molecular weight VWFM was also lacking in the early stage and even in the later stage after SCT. In contrast, in the group with FFP infusion, no apparent changes in VWFM patterns were found throughout SCT [65]. It remains unclear why such a phenomenon occurred, but one possible explanation may be the SEC injury caused by intensive chemotherapy and/or total body irradiation in the setting of SCT. Indeed, chemotherapy before SCT is a regimen with a high incidence of hepatic VOD, and total body irradiation causes radiation-induced liver disease [62, 63]. The amount of VWF released from injured SEC may be increased at first, but may thereafter decrease because the endothelial cells are extensively damaged [65]. After SCT, as damaged endothelial cells gradually regenerate, the release of VWF may increase, resulting in the appearance of high and intermediate VWFM. Under these circumstances, plasma ADAMTS13 may be consumed to degrade the large amounts of VWF. The imbalance caused by decreased ADAMTS13:AC versus increased production of VWF:AG before and during the early stage after SCT would contribute to a microcirculatory disturbance that could ultimately lead to VOD, especially in zone 3 of the hepatic lobule where hepatocytes are susceptible to damage induced by hypoxia [65]. The supplementation of ADAMTS13 by prophylactic FFP infusion may suppress the increase in VWF:AG that is extensively released from damaged SEC.

4.4 Liver transplantation

One of the serious complications in solid organ transplantation is the occurrence of sporadic thrombotic microangiopathies (TMAs) at an estimated frequency of 0.5–3.0% [66–68]. For instance, various degrees of thrombocytopenia are commonly observed after liver transplantation, especially during the first postoperative week, and some clinical studies have demonstrated that thrombocytopenia was significantly associated with poor prognosis [69]. The imbalance between endothelin and nitric oxide produced by the SEC may lead to active vasoconstriction, narrowing of the sinusoidal lumen, and subsequent sinusoidal microcirculatory disturbance [70]. During the past decade, the measurement of plasma ADAMTS13:AC was utilized as a differential diagnostic tool for TMAs [68], but its relevance to organ transplantation itself was not well evaluated.